The price-to-earnings ratio for Globus Medical Inc (NYSE: GMED) is above average at 113.67x. The 36-month beta value for GMED is also noteworthy at 1.14. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 7 rating it as “hold,” and 1 rating it as “sell.”
The public float for GMED is 111.76M, and at present, short sellers hold a 6.09% of that float. The average trading volume of GMED on July 26, 2024 was 1.03M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GMED) stock’s latest price update
Globus Medical Inc (NYSE: GMED)’s stock price has gone decline by -1.25 in comparison to its previous close of 72.66, however, the company has experienced a -0.25% decrease in its stock price over the last five trading days. zacks.com reported 2024-07-19 that In line with the company’s business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
GMED’s Market Performance
Globus Medical Inc (GMED) has experienced a -0.25% fall in stock performance for the past week, with a 6.44% rise in the past month, and a 39.48% rise in the past quarter. The volatility ratio for the week is 1.89%, and the volatility levels for the past 30 days are at 1.90% for GMED. The simple moving average for the last 20 days is 1.92% for GMED’s stock, with a simple moving average of 29.13% for the last 200 days.
Analysts’ Opinion of GMED
Many brokerage firms have already submitted their reports for GMED stocks, with Piper Sandler repeating the rating for GMED by listing it as a “Overweight.” The predicted price for GMED in the upcoming period, according to Piper Sandler is $80 based on the research report published on May 20, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see GMED reach a price target of $60. The rating they have provided for GMED stocks is “Buy” according to the report published on March 18th, 2024.
ROTH MKM gave a rating of “Buy” to GMED, setting the target price at $75 in the report published on October 20th of the previous year.
GMED Trading at 5.97% from the 50-Day Moving Average
After a stumble in the market that brought GMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.25% of loss for the given period.
Volatility was left at 1.90%, however, over the last 30 days, the volatility rate increased by 1.89%, as shares surge +5.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.55% upper at present.
During the last 5 trading sessions, GMED fell by -0.25%, which changed the moving average for the period of 200-days by +35.86% in comparison to the 20-day moving average, which settled at $70.58. In addition, Globus Medical Inc saw 34.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GMED starting from Norwalk Leslie V, who sale 1,000 shares at the price of $70.00 back on Jul 11 ’24. After this action, Norwalk Leslie V now owns 16,419 shares of Globus Medical Inc, valued at $70,000 using the latest closing price.
Lemaitre Dan, the Director of Globus Medical Inc, sale 63,300 shares at $64.61 during a trade that took place back on May 10 ’24, which means that Lemaitre Dan is holding 0 shares at $4,090,022 based on the most recent closing price.
Stock Fundamentals for GMED
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.61 for the gross margin
The net margin for Globus Medical Inc stands at 0.04. The total capital return value is set at 0.03. Equity return is now at value 2.28, with 1.88 for asset returns.
Based on Globus Medical Inc (GMED), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.46. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 7.03.
Currently, EBITDA for the company is 401.03 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 5.19. The receivables turnover for the company is 3.55for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.
Conclusion
In summary, Globus Medical Inc (GMED) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
